Celgene, Novartis Settle With Teva In Focalin IP Suits

Law360, New York (February 2, 2010, 2:14 PM EST) -- Celgene Corp. and Novartis Pharmaceuticals Corp. have settled a series of lawsuits against Teva Pharmaceuticals USA Inc. over its plan to market a generic version of attention deficit hyperactivity disorder treatment Focalin XR.

In stipulations filed in three separate lawsuits Monday in the U.S. District Court for the District of New Jersey, Celgene, Novartis and Teva agreed to dismiss all claims between them with prejudice. The parties will bear their own costs, according to the stipulations.

In December, the parties had filed stipulations asking the court...
To view the full article, register now.